Stock comparison
Eli Lilly
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$946.37B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 65B | 42D | LLY |
| Benjamin Graham | 76B | 54C | LLY |
| Philip Fisher | 75B | 50C | LLY |
| Peter Lynch | 64C | 84A | TGTX |
| Joel Greenblatt | 68B | 55C | LLY |
| Charlie Munger | 75B | 44D | LLY |
| Terry Smith | 66B | 37D | LLY |
Side-by-side metrics
| Metric | LLY | TGTX |
|---|---|---|
| Market cap | $946.37B | $6.51B |
| P/E (TTM) | 35.6x | 13.3x |
| EV/EBIT | 33.2x | 55.3x |
| ROIC (TTM) | 32.06% | 11.13% |
| Gross margin | 83.51% | 83.04% |
| Net margin | 34.98% | 65.95% |
| Revenue CAGR 5y | 23.17% | 2.1% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 1.3x |
| Dividend yield | 0.64% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.64%vs 0.0%+100%
- Market cap$946.37Bvs $6.51B+99%
- ROIC (TTM)32.06%vs 11.13%+65%
- EV/EBIT33.2xvs 55.3x+40%
TGTX leads on
- Revenue CAGR 5y2.1%vs 23.17%+89%
- P/E (TTM)13.3xvs 35.6x+63%
- Net margin65.95%vs 34.98%+47%
- Debt / Equity1.3xvs 1.4x+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.